Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan-Reference-Cited by-同舟云学术

Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan

Published:2019-10 Issue: Volume:85 Page:106219
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Weil Clara^ORCID,Gelerstein Shulamit,Sharman Moser Sarah,Chodick Gabriel^ORCID,Barit Ben-David Nava,Shalev Varda,Shofaniyeh Irena,Kamalov Ruth,Meytes Dina

Funder

Janssen Israel, J-C Health Care Ltd

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. Multiple Myeloma Epidemiology and Survival: A Unique Malignancy. Seminars in Oncology,2016

2. Treatment for high-risk smoldering myeloma;Kristinsson;N. Engl. J. Med.,2013

3. Prevalence, incidence and survival of smoldering multiple myeloma in the United States;Bartley;Blood Cancer J.,2016

4. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK;Phekoo;Br. J. Haematol.,2004

5. SEER Cancer Statistics Review, 1975-2014;National Cancer Institute,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complete blood and urine paraprotein tests as response assessments in multiple myeloma patients treated with bortezomib, cyclophosphamide, and dexamethasone;Chronic Diseases and Translational Medicine;2023-10-31

2. Kidney Transplantation and Clinical Outcomes in Patients With Multiple Myeloma: Evidence From the United States Nationwide Inpatient Sample;International Neurourology Journal;2023-09-30

3. Management and outcome of 500 multiple myeloma patients treated for first relapse outside clinical studies;Annals of Hematology;2023-08-30

4. Biological research on the occurrence and development of multiple myeloma and its treatment;Immunity, Inflammation and Disease;2023-05

5. Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experiment;Future Oncology;2022-08